Peptide intra-tumor injection for cancer immunotherapy: Enhancement of tumor cell antigenicity is a novel and attractive strategy

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1234-1236

  Nobuoka, Daisuke ^a,b   Yoshikawa, Toshiaki ^a   Fujiwara, Toshiyoshi ^b   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antigen derived peptide; Cancer immunotherapy; Cytotoxic T lymphocyte; Major histocompatibility complex class I; Tumor antigen

Indexed keywords

GLYPICAN 3; GLYPICAN 3[144-152]; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; OVALBUMIN [257-264]; PEPTIDE; PEPTIDE VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGENICITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL TRANSFER; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; IMMUNE DEFICIENCY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIGEN-DERIVED PEPTIDE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I; TUMOR ANTIGEN;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; INJECTIONS; MICE; MICE, INBRED C57BL; NEOPLASMS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84880682913     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23990     Document Type: Review

References (9)

1. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol 2004; 16:644-50; PMID:15342012; http://dx.doi.org/10.1016/j.coi. 2004.07.015.
2. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two selfantigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989-94; PMID:9916724.
3. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003; 170:2523-30; PMID:12594278.
4. Pudney VA, Metheringham RL, Gunn B, Spendlove I, Ramage JM, Durrant LG. DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells. Eur J Immunol 2010; 40:899-910; PMID:20039301; .
5. Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918-25; PMID:21281401; http://dx.doi.org/10. 1111/j.1349-7006.2011.01896.x.
6. Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, et al. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother 2012; In press; PMID:23143746; http://dx.doi.org/10.1007/s00262-012-1366-6.
7. Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, et al. Clinical implication of HLA class I expression in breast cancer. BMC Cancer 2011; 11:454; PMID:22014037; http://dx.doi.org/10.1186/1471-2407-11-454.
8. Lee HW, Min SK, Ju YS, Sung J, Lim MS, Yang DH, et al. Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal antipan HLA class I antibody, EMR8-5. J Gastrointest Surg 2011; 15:1336-43; PMID:21512844; http://dx.doi.org/10.1007/s11605-011-1545-3.
9. Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, et al. Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 2012; 62:303-8; PMID:22524657; http://dx.doi.org/10.1111/j.1440-1827.2012.02789.x.